NCT03938389View on ClinicalTrials.gov

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

February 8, 2024

Study Completion Date

June 30, 2026

Conditions
PreDiabetesImpaired Glucose ToleranceObesityBlood Pressure
Interventions
DRUG

Sacubitril-Valsartan Tab 97-103 MG

Participants will take Sacubitril-Valsartan for 26 weeks

DRUG

Valsartan 160mg

Participant will take Valsartan for 26 weeks

DRUG

Placebo Oral Tablet

Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center, Columbus

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Ohio State University

OTHER